• Publications
  • Influence
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. Expand
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
The classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes. Expand
Revised international prognostic scoring system for myelodysplastic syndromes.
This revised IPSS-R comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS and should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease. Expand
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis.
It is found that HSCs have unique cell-intrinsic mechanisms ensuring their survival in response to ionizing irradiation (IR), which include enhanced prosurvival gene expression and strong activation of p53-mediated DNA damage response. Expand
Subnuclear Compartmentalization of Immunoglobulin Loci During Lymphocyte Development
It is suggested that subnuclear positioning represents a novel means of regulating transcription and recombination of IgH and Igκ loci during lymphocyte development. Expand
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
It is demonstrated that specific alterations in miRNA expression distinguish AMLs with common translocations and imply that the deregulation of specific miRNAs may play a role in the development of leukemia with these associated genetic rearrangements. Expand
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Disease alleles that activate signal transduction are common in myeloid malignancies; however, there are additional unidentified mutations that contribute to myeloid transformation. Based on theExpand
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
Using a sensitive transfection-tumorigenicity assay, we have isolated a novel transforming gene from the DNA of two patients with chronic myelogenous leukemia. Sequence analysis indicates that theExpand
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
A new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only is proposed, providing clear prognostic classification in 91% of all patients. Expand
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
  • R. Reiter, Z. Gu, +9 authors O. Witte
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 17 February 1998
Flow cytometric analysis demonstrates that PSCA is expressed predominantly on the cell surface and is anchored by a GPI linkage, which supports P SCA as a target for prostate cancer diagnosis and therapy. Expand